Tomer Levy - 02 Oct 2024 Form 4 Insider Report for Augmedix, Inc.

Reporting relationship: SVP, ENGINEERING
Issuer ticker: N/A
Reported as of: 02 Oct 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Oct 2024, 13:14:33 UTC
Prior SEC filing: 27 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Todd Holvick, Attorney-in-Fact

Key filing fact

Tomer Levy filed Form 4 for Augmedix, Inc. on 04 Oct 2024.

Key facts

This page summarizes Tomer Levy's Form 4 filing for Augmedix, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Oct 2024, 13:14.

Change

Previous filing in this sequence was filed on 27 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AUGX transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value: $0
Shares: -105,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Tomer Levy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.

Footnote F2

Pursuant to the Merger Agreement, at the Effective Time, the restricted stock units were replaced with a cash incentive program, which preserves the compensation elements and vesting terms of the restricted stock units.